摘要
目的分析纳武利尤单抗与伊匹木单抗联合治疗不可手术切除的恶性胸膜间皮瘤纳入中国国家医保目录后的预算影响。方法基于医保支付方视角,建立5年(2024—2028年)预算影响分析模型,预测该联合疗法纳入医保后的预算变化。研究通过目标人群规模、药物市场份额及治疗成本等参数,对比纳入与未纳入医保两种情境下的医保支出差异,并采用单因素敏感性分析验证模型稳健性。结果纳入医保后,2024—2028年医保基金累计支出增加6664.5万元,主要源于药品费用的医保支付部分,但对基金总体负担影响有限。敏感性分析表明,药品价格、医保报销比例及覆盖率是预算变化的关键驱动因素。结论尽管该疗法纳入医保会增加医保支出,但其对基金整体压力影响可控。
Objective To evaluate the budget impact of the combination therapy of nivolumab and ipilimumab for the treatment of unresectable malignant pleural mesothelioma after its inclusion in the China's National Reimbuirsement Drug List(NRDL).Methods This study constructed a 5-year(2024—2028)budget impact analysis model from the perspective of the Chinese government health insurance authority to simulate the budget changes after the combination therapy of nivolumab and ipilimumab was included in the NRDL.The model analyzed factors such as the target population,drug market share,and treatment costs,comparing healthcare expenditures in scenarios with and without insurance coverage.One-way sensitivity analysis was performed to assess model robustness.Results After inclusion in the NRDL,the incremental expenditure from 2024 to 2028 mainly stems from health insurance payment portion of drug costs,with a cumulative increase of 66.645 million yuan.However,the overall financial impact on the insurance fund remains minimal.Sensitivity analysis showed that drug prices,reimbursement rates,and insurance coverage rates were the key factors affecting budget changes.Conclusion Although the combination therapy of nivolumab and ipilimumab included in the NRDL will increase expenditure,the impact on the overall fund burden is limited.
作者
杨运
赵娜
徐燕
赵杨
YANG Yun;ZHAO Na;XU Yan;ZHAO Yang(Henan Medical Price and Bidding Procurement Service Center,Zhengzhou 450000,Henan Province,China;Henan Medical College,Zhengzhou 450000,Henan Province,China;Fifth Affiliated Hospital of Zhengzhou University,Zhengzhou 450000,Henan Province,China)
出处
《世界临床药物》
2025年第5期465-470,共6页
World Clinical Drug
